ArticleBMC biology2026
cyberDMR: accurate and robust identification of differentially methylated regions from WGS-derived methylomes.
Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDifferentially methylated regions (DMRs) are essential regulatory features for characterizing epigenetic variation, understanding population-level differences, and interpreting haplotype-specific methylation patterns. However, existing DMR detection methods often show unstable performance under biologically challenging scenarios such as sparse CpG regions, low sequencing depth, small sample sizes, extreme region lengths, and subtle methylation differences. These limitations highlight the need for a more robust and versatile approach capable of achieving accurate and consistent DMR detection across diverse genomic contexts. To address these challenges, we developed cyberDMR, a robust and noise-resilient DMR detection framework that integrates coverage-adaptive smoothing, seed-growing clustering, and weighted beta regression to achieve stable performance under whole-genome sequencing (WGS) and varying sequencing conditions.
resultscyberDMR consistently achieved the highest F1-scores on real WGBS prostate cancer datasets, outperforming other strong-performing methods by 2-18%. This advantage was further supported by extensive simulations spanning diverse genomic and experimental scenarios, in which cyberDMR maintained stable and leading performance, achieving a mean F1-score of 99.7% (± 0.3%) and consistently outperforming competing methods across diverse simulated settings. When applied to long-read methylation datasets, cyberDMR enabled the identification of 107 biologically meaningful methylation regions, including 15 gene-associated regions influenced by cis-acting methylation quantitative trait loci (meQTLs) and 2 corresponding putative novel imprinting candidates, ZNF714 and NINJ2.
conclusionscyberDMR provides a robust and accurate framework for genome-wide DMR detection, capturing consistent inter-group methylation differences while preserving intra-group consistency across diverse sequencing conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.